Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Could Publish Drug GMP Data To Nudge Manufacturing Improvements

This article was originally published in The Tan Sheet

Executive Summary

Batch failure and other measures manufacturers commonly track could be aggregated into an industry-wide index FDA would use to help make inspection decisions. CDER compliance chief Howard Sklamberg says FDA wants more predictive measures to find quality issues, rather than lagging metrics such as recalls or adverse events.

You may also be interested in...



FDA To Create Quality Metrics To Help Fine-Tune Risk-Based Enforcement

FDA will work with stakeholders to identify quality indicators that drug firms would track and report to help the agency improve surveillance and fine-tune risk-based criteria for inspections and enforcement, FDA’s Sklamberg said. CDER’s Office of Compliance also is focused on improving supply chain oversight and clarifying contract manufacturer responsibilities.

FDA To Create Quality Metrics To Help Fine-Tune Risk-Based Enforcement

FDA will work with stakeholders to identify quality indicators that drug firms would track and report to help the agency improve surveillance and fine-tune risk-based criteria for inspections and enforcement, FDA’s Sklamberg said. CDER’s Office of Compliance also is focused on improving supply chain oversight and clarifying contract manufacturer responsibilities.

FDA Drug Detention Regulation Follows Devices Oversight Model

A proposed rule implementing new FDASIA authority to administratively detain drugs believed to be adulterated or misbranded largely mirrors regulations already in place for medical devices, FDA says.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS106523

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel